TP53 and prostate cancer: Mechanistically, p53 transcriptionally activates the downstream ubiquitin ligase AIP4, and promotes degradation of the chemokine receptor CXCR4 to block the trafficking of CXCR4-positive prostate cancer cells to the bone marrow.